ReviewClinical and vaccine immunology : CVI2013
Targeting the "cytokine storm" for therapeutic benefit.
Review in Clinical and vaccine immunology : CVI, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 185 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
185 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Therapeutic Effects of Alkaloids on Influenza: A Systematic Review and Meta-Analysis of Preclinical Studies.International journal of molecular sciences · 2025Pooled it
- Pooled it
- A systematic meta-analysis of immune signatures in patients with COVID-19.Reviews in medical virology · 2021Pooled it
- COVID-19 and Major Organ Thromboembolism: Manifestations in Neurovascular and Cardiovascular Systems.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2021Pooled it
- Pooled it
- Special Issue "The Role of Toll-like Receptors (TLRs) in Infection and Inflammation: Third Edition".International journal of molecular sciences · 2026Article
- MVP Inhibits Influenza A Virus-Induced Ferroptosis by Targeting IRF1 and Increasing FSP1 Activity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Myeloid-Derived Suppressor Cells in Sepsis: Pathophysiology, Duality, and Therapeutic Frontiers.Shock (Augusta, Ga.) · 2026Review
- Andrographolide Suppresses Influenza A Virus-Induced Pyroptosis via PI3K/AKT-Mediated Caspase-3/GSDME Inactivation.Biomedicines · 2026Article
- Hyper-inflammation and immunosuppression: redefining sepsis therapy using modern approaches.Frontiers in pharmacology · 2026Review
- Sepsis and the diverse organ-gastrointestinal tract axis.World journal of critical care medicine · 2025Review
- Integrated Transcriptomic Analysis of S100A8/A9 as a Key Biomarker and Therapeutic Target in Sepsis Pathogenesis and AI Drug Repurposing.International journal of molecular sciences · 2025Article
- Glutamate utilization fuels rapid production of mitochondrial ROS in dendritic cells and drives systemic inflammation during tularemia.Science advances · 2025Article
- A feedback loop between DNA damage, genomic instability, and cytoplasmic DNA sensing contributes to cytokine production in COVID-19.Archives of virology · 2025Review
- Recruitment of pulmonary intravascular macrophages in SARS-CoV-2 infected hamsters.Cell and tissue research · 2025Article
- The Novel H10N3 Avian Influenza Virus Triggers Lethal Cytokine Storm by Activating Multiple Forms of Programmed Cell Death in Mammalian Lungs.International journal of molecular sciences · 2025Article
- Coronary Implications of COVID-19.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2025Review
- Advanced lung cancer inflammation index and short-term mortality in sepsis: a retrospective analysis.Frontiers in nutrition · 2025Article
- The immune response toFrontiers in microbiology · 2025Review
- Article
125 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation is the body's first line of defense against infection or injury, responding to challenges by activating innate and adaptive responses. Microbes have evolved a diverse range of strategies to avoid triggering inflammatory responses. However, some pathogens, such as the influenza virus and the Gram-negative bacterium Francisella tularensis, do trigger life-threatening "cytokine storms" in the host which can result in significant pathology and ultimately death. For these diseases, it has been proposed that downregulating inflammatory immune responses may improve outcome. We review some of the current candidates for treatment of cytokine storms which may prove useful in the clinic in the future and compare them to more traditional therapeutic candidates that target the pathogen rather than the host response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.